Noncalcemic actions of vitamin D receptor ligands

Endocrine Reviews

Volumn 26, Issue 5, 2005, Pages 662-687

  Nagpal, Sunil ^a   Na, Songqing ^a   Rathnachalam, Radhakrishnan ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; 2BETA (3 HYDROXYPROPOXY)CALCITRIOL; ALFACALCIDOL; CALCIPOTRIOL; CALCITRIOL; COLECALCIFEROL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIGAND; SEOCALCITOL; STEROID HORMONE; TACALCITOL; THYROID HORMONE; TRANSCRIPTION FACTOR AP 1; VITAMIN D RECEPTOR;

ACTINIC KERATOSIS; AUTOIMMUNE DISEASE; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER CELL; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; COLON CANCER; CRYSTAL STRUCTURE; CYTOARCHITECTURE; ENTERITIS; GENE EXPRESSION; GRAFT REJECTION; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOMODULATION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LEUKEMIA; LEUKEMIA CELL; LIVER CELL CARCINOMA; MULTIPLE SCLEROSIS; MYELODYSPLASIA; NONHUMAN; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PHOTOAGING; PHYSIOLOGY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SEBORRHEIC DERMATITIS; SQUAMOUS CELL CARCINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET CELL;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; LIGANDS; MICE; MODELS, MOLECULAR; NEOPLASMS; OSTEOPOROSIS; PSORIASIS; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 23744437421     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2004-0002     Document Type: Review

References (284)

1. Pinette KV, Yee YK, Amegadzie BY, Nagpal S 2003 Vitamin D receptor as a drug discovery target. Mini Rev Med Chem 3:193-204
2. Fogh K, Kragballe K 2000 Recent developments in vitamin D analogs. Curr Pharm Des 6:961-972
3. Gollnick H, Menke T 1998 Current experience with tacalcitol ointment in the treatment of psoriasis. Curr Med Res Opin 14:213-218
4. Kragballe K 1995 Calcipotriol: a new drug for topical psoriasis treatment. Pharmacol Toxicol 77:241-246
5. Slatopolsky E, Brown AJ 2002 Vitamin D analogs for the treatment of secondary hyperparathyroidism. Blood Purif 20:109-112
6. Sairanen S, Karkkainen M, Tahtela R, Laitinen K, Makela P, Lamberg-Allardt C, Valimaki MJ 2000 Bone mass and markers of bone and calcium metabolism in postmenopausal women treated with 1,25-dihydroxyvitamin D (Calcitriol) for four years. Calcif Tissue Int 67:122-127
7. Richy F, Ethgen O, Bruyere O, Reginster JY 2004 Efficacy of α-calcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15:301-310
8. Sutton AL, MacDonald PN 2003 Vitamin D: more than a "bonea- fide" hormone. Mol Endocrinol 17:777-791
9. Barsony J, Pike JW, DeLuca HF, Marx SJ 1990 Immunocytology with microwave-fixed fibroblasts shows 1 α,25-dihydroxyvitamin D3-dependent rapid and estrogen-dependent slow reorganization of vitamin D receptors. J Cell Biol 111:2385-2395
10. Cheskis B, Freedman LP 1994 Ligand modulates the conversion of DNA-bound vitamin D3 receptor (VDR) homodimers into VDR-retinoid X receptor heterodimers. Mol Cell Biol 14:3329-3338
11. Prufer K, Racz A, Lin GC, Barsony J 2000 Dimerization with retinoid X receptor promotes nuclear localization and subnuclear targeting of vitamin D receptor. J Biol Chem 275:41114-41123
12. Thompson PD, Jurutka PW, Whitfield GK, Myskowski SM, Eichhorst KR, Dominguez CE, Haussler CA, Haussler MR 2002 Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem Biophys Res Commun 299:730-738
13. Crofts LA, Hancock MS, Morrison NA, Eisman JA 1998 Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc Natl Acad Sci USA 95:10529-10534
14. Dong X, Craig T, Xing N, Bachman LA, Paya CV, Weih F, McKean DJ, Kumar R, Griffin MD 2003 Direct transcriptional regulation of RelB by 1α,25-dihydroxyvitamin D3 and its analogs: physiologic and therapeutic implications for dendritic cell function. J Biol Chem 278:49378-49385
15. Liu SM, Koszewski N, Lupez M, Malluche HH, Olivera A, Russell J 1996 Characterization of a response element in the 5′-flanking region of the avian (chicken) PTH gene that mediates negative regulation of gene transcription by 1,25-dihydroxyvitamin D3 and binds the vitamin D3 receptor. Mol Endocrinol 10:206-215
16. Alroy I, Towers TL, Freedman LP 1995 Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol 15:5789-5799
17. Takeuchi A, Reddy GS, Kobayashi T, Okano T, Park J, Sharma S 1998 Nuclear factor of activated T cells (NFAT) as a molecular target for 1α,25-dihydroxyvitamin D3-mediated effects. J Immunol 160:209-218
18. Harant H, Andrew PJ, Reddy GS, Foglar E, Lindley IJ 1997 1α,25-dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nuclear-factor-κB-mediated interleukin-8 gene expression. Eur J Biochem 250:63-71
19. Kerner SA, Scott RA, Pike JW 1989 Sequence elements in the human osteocalcin gene confer basal and inducible response to hormonal vitamin D3. Proc Natl Acad Sci USA 86:4455-4459
20. Lomri A, Baron R 1992 1α,25-dihydroxyvitamin D3 regulates the transcription of carbonic anhydrase II mRNAin avian myelomonocytes. Proc Natl Acad Sci USA 89:4688-4692
21. Noda M, Vogel RL, Craig AM, Prahl J, DeLuca HF, Denhardt DT 1990 Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (Spp-1 or osteoponstin) gene expression. Proc Natl Acad Sci USA 87:9995-9999
22. Quelo I, Machuca I, Jurdic P 1998 Identification of a vitamin D response element in the proximal promoter of the chicken carbonic anhydrase II gene. J Biol Chem 273:10638-10646
23. 3 augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun 290:650-655
24. Kitazawa S, Kajimoto K, Kondo T, Kitazawa R 2003 Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J Cell Biochem 89:771-777
25. Cao X, Ross FP, Zhang L, MacDonald PN, Chappel J, Teitelbaum SL 1993 Cloning of the promoter for the avian integrin β3 subunit gene and its regulation by 1,25-dihydroxyvitamin D3. J Biol Chem 268:27371-27380
26. Darwish HM, DeLuca HF 1992 Identification of a 1,25-dihydroxyvitamin D3-response element in the 5′-flanking region of the rat calbindin D-9k gene. Proc Natl Acad Sci USA 89:603-607
27. Freedman LP 1999 Transcriptional targets of the vitamin D3 receptor -mediating cell cycle arrest and differentiation. J Nutr 129:581
28. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP 1996 Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142-153
29. Ohyama Y, Ozono K, Uchida M, Shinki T, Kato S, Suda T, Yamamoto O, Noshiro M, Kato Y 1994 Identification of a vitamin D-responsive element in the 5′-flanking region of the rat 25-hydroxyvitamin D3 24-hydroxylase gene. J Biol Chem 269:10545-10550
30. Bikle DD, Tu C-L, Xie Z, Oda Y 2003 Vitamin D regulated keratinocyte differentiation: role of coactivators. J Cell Biochem 88:290-295
31. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ 2002 Vitamin D receptor as an intestinal bile acid receptor. Science 296:1313-1316
32. Peng L, Malloy PJ, Feldman D 2004 Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 18:1109-1119
33. 3 and the immune system. Mol Cell Endocrinol 43:113-122
34. Muller K, BendtzenK1996 1,25-Dihydroxyvitamin D3 as a natural regulator of human immune functions. J Invest Dermatol Symp Proc 1:68-71
35. 3. J Clin Invest 101:252-262
36. Tobler A, Gasson J, Reichel H, Norman AW, Koeffler HP 1987 Granulocyte-macrophage colony-stimulating factor. Sensitive and receptor-mediated regulation by 1,25-dihydroxyvitamin D3 in normal human peripheral blood lymphocytes. J Clin Invest 79:1700-1705
37. Matsumoto K, Hashimoto K, Higashiyama M, Nishida Y, Yoshikawa K 1990 Growth-inhibitory effects of 1,25-dihydroxyvitamin D3 on normal and psoriatic keratinocytes. Br J Dermatol 123:93-98
38. 3 analogs. J Invest Dermatol Symp Proc 1:78-81
39. Russell J, Lettieri D, Sherwood LM 1986 Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene. Endocrinology 119:2864-2866
40. Falzon M 1996 DNA sequences in the rat parathyroid hormonerelated peptide gene responsible for 1,25-dihydroxyvitamin D3-mediated transcriptional repression. Mol Endocrinol 10:672-681
41. Kremer R, Karaplis AC, Henderson J, Gulliver W, Banville D, Hendy GN, GoltzmanD1991 Regulation of parathyroid hormonelike peptide in cultured normal human keratinocytes. Effect of growth factors and 1,25 dihydroxyvitamin D3 on gene expression and secretion. J Clin Invest 87:884-893
42. 3. Proc Natl Acad Sci USA 89:8097-8101
43. Nishishita T, Okazaki T, Ishikawa T, Igarashi T, Hata K, Ogata E, Fujita T 1998 A negative vitamin D response DNA element in the human parathyroid hormone-related peptide gene binds to vitaminD receptor along with Ku antigen to mediate negative gene regulation by vitamin D. J Biol Chem 273:10901-10907
44. Towers TL, Freedman LP 1998 Granulocyte-macrophage colonystimulating factor gene transcription is directly repressed by the vitamin D3 receptor. Implication for allosteric influences on nuclear receptor structure and function by a DNA element. J Biol Chem 273:10338-10348
45. Hermanson O, Glass CK, Rosenfeld MG 2002 Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol Metabol 13:55-60
46. Lee JW, Ryan F, Swaffield JC, Johnston SA, Moore DD 1995 Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature 374:91-94
47. Masuyama H, MacDonald PN 1998 Proteasome-mediated degradation of the vitamin D receptor (VDR) and a putative role for SUG1 interaction with the AF-2 domain of VDR. J Cell Biochem 71:429-440
48. Jaaskelainen T, Ryhanen S, Mahonen A, DeLuca HF, Maenpaa PH 2000 Mechanism of action of superactive vitamin D analogs through regulated receptor degradation. J Cell Biochem 76:548-558
49. Fraser RA, Rossignol M, Heard DJ, Egly J-M, Chambon P 1997 Sug1, a putative transcriptional mediator and subunit of the PA700 proteasome complex, is a DNA helicase. J Biol Chem 272:7122-7126
50. Zhang C, Baudino TA, Dowd DR, Tokumaru H, Wang W, Mac-Donald PN 2001 Ternary complexes and cooperative interplay between NCoA-62/Ski-interacting protein and steroid receptor coactivators in vitamin D receptor-mediated transcription. J Biol Chem 276:40614-40620
51. Barry JB, Leong GM, Church WB, Issa LL, Eisman JA, Gardiner EM 2003 Interactions of SKIP/NCoA-62, TFIIB and retinoid X receptor with vitamin D receptor helix H10 residues. J Biol Chem 278:8224-8228
52. Mengus G, May M, Carre L, Chambon P, Davidson I 1997 Human TAF(II)135 potentiates transcriptional activation by the AF-2s of the retinoic acid, vitamin D3, and thyroid hormone receptors in mammalian cells. Genes Dev 11:1381-1395
53. Lavigne AC, Mengus G, Gangloff YG, Wurtz JM, Davidson I 1999 Human TAF(II)55 interacts with the vitamin D(3) and thyroid hormone receptors and with derivatives of the retinoid X receptor that have altered transactivation properties. Mol Cell Biol 19:5486-5494
54. Mengus G, Gangloff YG, Carre L, Lavigne AC, Davidson I 2000 The human transcription factor IID subunit human TATA-binding protein-associated factor 28 interacts in a ligand-reversible manner with the vitamin D(3) and thyroid hormone receptors. J Biol Chem 275:10064-10071
55. Rachez C, Suldan Z, Ward J, Chang CP, Burakov D, Erdjument-Bromage H, Tempst P, Freedman LP 1998Anovel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes Dev 12:1787-1800
56. Rachez C, Gamble M, Chang C-PB, Atkins GB, Lazar MA, Freedman LP 2000 The DRIP complex and SRC-1/p160 coactivators share similar nuclear receptor binding determinants but constitute functionally distinct complexes. Mol Cell Biol 20:2718-2726
57. Hu X, Li Y, Lazar MA 2001 Determinants of CoRNR-dependent repression complex assembly on nuclear hormone receptors. Mol Cell Biol 21:1747-1758
58. Webb P, Anderson CM, Valentine C, Nguyen P, Marimuthu A, West BL, Baxter JD, Kushner PJ 2000 The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs). Mol Endocrinol 14:1976-1985
59. Rochel N, Tocchini-Valentini G, Egea PF, Juntunen K, Garnier JM, Vihko P, Moras D 2001 Functional and structural characterization of the insertion region in the ligand binding domain of the vitamin D nuclear receptor. Eur J Biochem 268:971-979
60. Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D 2000 The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 5:173-179
61. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 375:377-382
62. Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D, Gronemeyer H 1996 A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol 3:87-94
63. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 378:681-689
64. Nakajima S, Yamagata M, Sakai N, Ozono K 1998 Characterization of the activation function-2 domain of the human 1,25-dihydroxyvitamin D3 receptor. Mol Cell Endocrinol 139:15-24
65. Mizwicki MT, Keidel D, Bula CM, Bishop JE, Zanello LP, Wurtz JM, Moras D, Norman AW 2004 Identification of an alternative ligand-binding pocket in the nuclear vitamin D receptor and its functional importance in 1α,25(OH)2- vitamin D3 signaling. Proc Natl Acad Sci USA 101:12876-12881
66. Wang Y, Chirgadze NY, Briggs SL, Khan S, Jensen EL, Burris TP, A second binding site for hydroxytamoxifene within the ligandbinding domain of estrogen receptor β. Program of the 85th Annual Meeting of The Endocrine Society, Philadelphia, PA, 2003, p 106 (Abstract OR34-1)
67. Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, Kawakami T, Arioka K, Sato H, Uchiyama Y, Masushige S, Fukamizu A, Matsumoto T, Kato S 1997 Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 16:391-396
68. Li YC, Pirro AE, Amling M, Delling G, Baron R, Bronson R, Demay MB 1997 Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 94:9831-9835
69. Kato S, Takeyama K, Kitanaka S, Murayama A, Sekine K, Yoshizawa T 1999 In vivo function of VDR in gene expression-VDR knock-out mice. J Steroid Biochem Mol Biol 69:247-251
70. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG 2003 Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 17:509-511
71. Van Cromphaut SJ, Dewerchin M, Hoenderop JG, Stockmans I, Van Herck E, Kato S, Bindels RJ, Collen D, Carmeliet P, Bouillon R, Carmeliet G 2001 Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci USA 98:13324-13329
72. Sakai Y, Kishimoto J, Demay MB 2001 Metabolic and cellular analysis of alopecia in vitamin D receptor knockout mice. J Clin Invest 107:961-966
73. Chen CH, Sakai Y, Demay MB 2001 Targeting expression of the human vitamin D receptor to the keratinocytes of vitamin D receptor null mice prevents alopecia. Endocrinology 142:5386-5389
74. Hsieh JC, Sisk JM, Jurutka PW, Haussler CA, Slater SA, Haussler MR, Thompson CC 2003 Physical and functional interaction between the vitamin D receptor and hairless corepressor, two proteins required for hair cycling. J Biol Chem 278:38665-38674
75. Li M, Indra AK, Warot X, Brocard J, Messaddeq N, Kato S, Metzger D, Chambon P 2000 Skin abnormalities generated by temporally controlled RXRα mutations in mouse epidermis. Nature 407:633-636
76. Sakai Y, Demay MB 2000 Evaluation of keratinocyte proliferation and differentiation in vitamin D receptor knockout mice. Endocrinology 141:2043-2049
77. Zinser GM, Sundberg JP, Welsh J 2002 Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis 23:2103-2109
78. Yagishita N, Yamamoto Y, Yoshizawa T, Sekine K, Uematsu Y, Murayama H, Nagai Y, Krezel W, Chambon P, Matsumoto T, Kato S 2001 Aberrant growth plate development in VDR/RXR γ double null mutant mice. Endocrinology 142:5332-5341
79. DeLuca HF, Cantorna MT 2001 Vitamin D: its role and use in immunology. FASEB J 15:2579-2585
80. Mathieu C, Adorini L 2002 The coming age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends Mol Med 8:174-179
81. Adorini L 2002 Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Int Immunopharmacol 2:1017-1028
82. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC 1983 1,25-Dihydroxyvitamin D3 receptors in human leukocyte. Science 221:1181-1183
83. Brennan A, Katz DR, Nunn JD, Barker S, Hewison M, Fraher LJ, O'Riordan JL 1987 Dendritic cells from human tissues express receptors for the immunomodulatory vitamin D3 metabolite, dihydroxycholecalciferol. Immunology 61:457-461
84. Veldman CM, Cantorna MT, DeLuca HF 2000 Expression of 1,25-dihydroxvatamin D3 receptor in the immune system. Arch Biochem Biophys 374:334-338
85. Morgan JW, Kouttab N, Ford D, Maizel AL 2000 Vitamin D-mediated gene regulation in phenotypically defined B cell subpopulations. Endocrinology 141:3225-3234
86. Koizumi T, Nakao Y, Matsui T, Nakagawa T, Matsuda AS, Komoriya K 1985 Effect of corticosteroid and 1,25R-dihydroxyvitamin D3 administration on lymphoproliferation and autoimmune disease in MRL/MRL-lpr/lpr mice. Int Arch Allergy Appl Immunol 77:396-404
87. Mathieu C, Casteels K, Waer M, Laureys J, Valckx D, Bouillon R 1998 Prevention of diabetes recurrence after syngeneic islet transplantation in NOD by 1a,25(OH)2D3 analogues of in combination with cyclosporin A: mechanism of action involves an immune shift from Th1 to Th2. Transplant Proc 30:541
88. Gysemans C, Van Etten E, Overbergh L, Verstuyf A, Waer M, Bouillon R, Mathieu C 2002 Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-β in combination with an analogue of 1α,25-dihydroxyvitamin D3. Clin Exp Immunol 128:213
89. Overbergh L, Decallonne B, Waer M, Rutgeerts O, Valckx D, Casteels KM, Laureys J, Bouillon R, Mathieu C 2000 1α,25-dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/Thelper 2 immune shift in NOD mice immunized with GAD65 (p524-543). Diabetes 49:1301-1307
90. Mauricio D, Mandrup-Poulsen T, Nerup J 1996 Vitamin D analogues in insulin-dependent diabetes mellitus and other autoimmune diseases: a therapeutic perspective. Diabetes Metab Rev 12:57-68
91. Mathieu C, Waer M, Casteels K, Laureys J, Bouillon R 1995 Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology 136:866-872
92. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L 2002 A 1α,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 51:1367-1374
93. Cantorna MT, Hayes CE, DeLuca HF 1998 1,25-dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 128:68-72
94. Larsson P, Mattsson L, Klareskog L, Johnsson C 1998 A vitamin D analogue (MC1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia. Clin Exp Immunol 114:277-283
95. Tsuji M, Fujii K, Nakano T, Nishii Y 1994 1α-hydroxyvitamin D3 inhibits type II collagen-induced arthritis in rats. FEBS Lett 337:248-250
96. Garcion E, Sindji L, Nataf S, Brachet P, Darcy F, Montero-Menei CN 2003 Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system. Acta Neuropathol 105:438-448
97. Meehan TF, DeLuca HF 2002 CD8+ T cells are not necessary for 1,25-dihydroxyvitmin D3 to suppress experimental autoimmune encephalomyelitis in mice. Proc Natl Acad Sci USA 99:5557-5560
98. Nashold FE, Hoag KA, Goverman J, Hayes CE 2001 Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D3 prevention of experimental autoimmune encephalomyelitis. J Neuroimmunol 119:16-29
99. Nashold FE, Miller DJ, Hayes CE 2000 1,25-dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 103:171-179
100. Cantorna MT, Woodward WD, Hayes CE, DeLuca HF 1998 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-β 1 and IL-4. J Immunol 160:5314-5319
101. Hayes CE, Cantorna MT, DeLuca HF 1997 Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med 216:21-27
102. Cantorna MT, Munsick C, Bemiss C, Mahon BD 2000 1,25- dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 130:2648-2652
103. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH 2000 A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100:655-669
104. Mattner F, Smiroldo S, Galbiati F, Muller M, Di Lucia P, Poliani PL, Martino G, Panina-Bordignon P, Adorini L 2000 Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur J Immunol 30:498-508
105. Cantorna MT, Hayes C, DeLuca HF 1996 1,25-dihydroxyvitmin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 93:7861-7864
106. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul FHJ, O'Garra A 1998 1,25-dihydroxyvitmin D3 has a direct effect on naïve CD4+ T cells to enhance the development of Th2 cells. J Immunol 167:4974-4980
107. Feldman M, Brennan FM, Maini RN 1996 Rheumatoid arthritis. Cell 85:307-310
108. Kroger H, Penttila IM, Alhava EM 1993 Low serum vitamin D metabolites in women with rheumatoid arthritis. Scand J Rheumatol 22:172-177
109. Huckins D, Felson DT, Holick M 1990 Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: a pilot study. Arthritis Rheum 33:1723-1727
110. Andjelkovic Z, Vojinovic J, Pejnovic N, Andjelkovic Z, Vojinovic J, Pejnovic N 1999 Disease modifying and immunomodulatory effect of high dose 1α(OH)2D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 17:452-456
111. Gerstenfeld LC, Kelly CM, von Deck M, Lian JB 1990 Effect of 1,25-dihydroxyvitamin D3 on induction of chondrocyte maturation in tissue culture: extracellular matrix gene expression and morphology. Endocrinology 49:26-31
112. Tetlow LC, Woolley DE 1999 The effects of 1 α,25-dihydroxyvitamin D(3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion. Arthritis Res 1:63-70
113. Aranda R, Sydora BC, McAillster PL, Binder SW, Yang HY, Targan SR, Kronenberg M 1997 Analysis of intestinal lymphocyte in mouse colitis mediated by transfer CD4+CD45Rbhi T cell in SCID recipient. J Immunol 158:3464-3473
114. Bragenholt S, Claesson MM 1998 Increased intracellular Th1 cytokine in SCID mice in inflammatory bowel disease. Eur J Immunol 28:379-389
115. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W 1993 Interleukin-10 deficient mice develop chronic enterocolitis. Cell 75:263-274
116. Thomas MG, Nugent KP, Forbes A, Williamson RC 1994 Calcipotriol inhibits rectal epithelial cell proliferation in ulcerative protocolitis. Gut 35:1718-1720
117. Stio M, Bonanomi AG, d'Albasio G, Treves C 2001 Suppressive effect of 1,23-dihydroxyvitamin D3 and its anlogues EB1089 and KH1060 on T lymphocyte proliferation in active ulcerative colitis. Biochem Pharmacol 61:365-371
118. Benoist C, Mathis D 1997 Cell death mediations in autoimmune diabetes-no shortage of suspects. Cell 89:1-3
119. Atkinson MA, Leiter EH 1999 The NOD model of type I diabetes: as good as it gets? Nat Med 5:601-604
120. Giulietti A, Gysemans C, Stoffels K, et al 2004 Vitamin D deficiency in early life accelerates Type 1 diabetes in non-obese diabetic mice. Diabetologia 47:451-462
121. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R 1994 Prevention of autoimmune diabetes in NOD mice by 1,25-dihydroxyvitamin D3. Diabetologia 37:552-558
122. 3: 22-oxa-1α,25-dihydroxyvitamin D3. J Nutr Sci Vitaminol 36:21-31
123. Matsui T, Takahashi R, Nakao Y, Koizumi T, Katakami Y, Mihara K, Sugiyama T, Fujita T 1986 1,25-Dihydroxyvitamin D3-regulated expression of genes involved in human T-lymphocyte proliferation and differentiation. Cancer Res 46:5827-5831
124. Tsoukas CD, Provvedini DM, Manolagas SC 1984 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. Science 224:1438-1440
125. Rigby WF, Stacy T, Fanger MW 1984 Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J Clin Invest 74:1451-1455
126. Penna G, Adorini L 2000 1 α,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164:2405-2411
127. Lemire JM, Ince A, TakashimaM1992 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity 12:143-148
128. Hullett DA, Cantorna MT, Redaelli C, Humpal-Winter J, Hayes CE, Sollinger HW, Deluca HF 1998 Prolongation of allograft survival by 1,25-dihydroxyvitamin D3. Transplantation 66:824-828
129. Redaelli CA 2001 1α, 25-Dihydroxycholecalciferol reduces rejection and improves survival in rat liver allografts. Hepatology 34:926-934
130. van Etten E, Gysemans C, Verstuyf A, Bouillon R, MathieuC2001 Immunomodulatory properties of a 1,25-dihydroxyvitamin D3 analogue combined with IFNβ in an animal model of syngeneic islet transplantation. Transplant Proc 33:2319
131. Gysemans C, Waer M, Laureys J, Bouillon R, Mathieu C 2001 A combination of KH1060, a vitamin D3 analogue, and cyclosporin prevents early graft failure and prolongs graft survival of xenogeneic islets in nonobese diabetic mice. Transplant Proc 33:2365
132. Bertolini DL, Araújo PRB, Silva RNC, Duarte AJSD, Tzanno-Martins CB 1999 Immunomodulatory effects of vitamin D analog KH1060 on an experimental skin transplantation model. Transplant Proc 31:2998-2999
133. Veyron P, Pamphile R, Binderup L, Touraine J-L 1993 Two novel vitamin D analogues, KH 1060 and CB 966, prolong skin allograft survival in mice. Transpl Immunol 1:72-76
134. Raisanen-Sokolowski AK, Pakkala IS, Samila SP, Binderup L, Hayry PJ, Pakkala ST 1997 A vitamin D analog, MC1288, inhibits adventitial inflammation and suppresses intimal lesions in rat aortic allografts. Transplantation 63:936-941
135. Dequeker J, Van Cleemput J, Declerck K, Mbuyi-Muamba JM 1997 Role of alfacalcidiol on bone quality and immunomodulation in autoimmune disease and organ transplantation. Calcif Tissue Int 60:128-129
136. Sambrook P 1999 Alfacalcidol and calcitriol in the prevention of bone loss after organ transplantation. Calcif Tissue Int 65:341-343
137. Briffa NK, Keogh AM, Sambrook PN, Eisman JA 2003 Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol. Transplantation 75:2133-2134
138. Bhalla AK, Amento EP, Serog B, Glimcher LH 1984 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 133:1748-1754
139. Rigby WF, Denome S, FangerMW1987 Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest 79:1659-1664
140. Banchereau J, Steinman RM 1998 Dendritic cells and the control of immunity. Nature 392:245-252
141. Zhou LJ, Tedder TF 1995 Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 154:3821-3835
142. Jonuleit H, Schmitt E, Steinbrink K, Enk AH 2001 Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 22:394-400
143. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K 2000 Immunobiology of dendritic cells. Annu Rev Immunol 18:767-811
144. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R 2001 Dendritic cell modulation by 1α,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 98:6800-6805
145. Berer A, Stockl J, Majdic O, Wagner T, Kollars M, Lechner K, Geissler K, Oehler L 2000 1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. Exp Hematol 28:575-583
146. Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, Allavena P, Di Carlo V 2000 Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 164:4443-4451
147. Adorini L, Penna G, Giarratana N, UskokovicM2003 Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem 88:227-233
148. Feldman D, Chen T, Hirst M, Colston K, Karasek M, Cone C 1980 Demonstration of 1,25-dihydroxyvitamin D3 receptors in human skin biopsies. J Clin Endocrinol Metab 51:1463-1465
149. Morimoto S, Kumahara Y 1985 A patient with psoriasis cured by 1 α-hydroxyvitamin D3. Med J Osaka Univ 35:51-54
150. Nagpal S, Lu J, Boehm MF 2001 Vitamin D analogs: mechanism of action and therapeutic applications. Curr Med Chem 8:1661-1679
151. Langner A, Stapor W, Ambroziak M 2001 Efficacy and tolerance of topical calcitriol 3 microg g(-1) in psoriasis treatment: a review of our experience in Poland. Br J Dermatol 144(Suppl 58):11-16
152. Barker JN, Berth-Jones J, Groves R, Omerod AD, Rizova E, Griffiths CE 2003 Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3 microg/g ointment; no correlation with extent of psoriasis. J Dermatolog Treat 14:14-21
153. Ramsay CA, Berth-Jones J, Brundin G, Cunliffe WJ, Dubertret L, van de Kerkhof PC, Menne T, Wegmann E 1994 Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 189:260-264
154. DiSepio D, Chandraratna RA, Nagpal S 1999 Novel approaches for the treatment of psoriasis. Drug Discov Today 4:222-231
155. Camarasa JM, Ortonne JP, Dubertret L 2003 Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatolog Treat 14:8-13
156. Oishi Y, Fu ZW, Ohnuki Y, Kato H, Noguchi T 2002 Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment: effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. Br J Dermatol 147:859-868
157. Lahfa M, Mrowietz U, Koenig M, Simon JC 2003 Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis. Eur J Dermatol 13:261-265
158. Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, Kaufmann R, Rogers S, van de Kerkhof PC, Hanssen LI, Tegner E, Burg G, Talbot D, Chu A 2003 Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 48:48-54
159. Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, Douglas WS, Lowson D, Mascaro JM, Murphy GM, Stymne B 2002 A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 205:389-393
160. Takahashi H, Ibe M, Kinouchi M, Ishida-Yamamoto A, Hashimoto Y, IizukaH2003 Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 31:21-28
161. Pillai S, Bikle DD 1991 Role of intracellular-free calcium in the cornified envelope formation of keratinocytes: differences in the mode of action of extracellular calcium and 1,25 dihydroxyvitamin D3. J Cell Physiol 146:94-100
162. Ratnam AV, Bikle DD, Cho JK 1999 1,25 Dihydroxyvitamin D3 enhances the calcium response of keratinocytes. J Cell Physiol 178:188-196
163. Kang S, Yi S, Griffiths CE, Fancher L, Hamilton TA, Choi JH 1998 Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol 138:77-83
164. Michel G, Gailis A, Jarzebska-Deussen B, Muschen A, Mirmohammadsadegh A, Ruzicka T 1997 1,25-(OH)2-vitamin D3 and calcipotriol induce IL-10 receptor gene expression in human epidermal cells. Inflamm Res 46:32-34
165. Hellerstedt BA, Pienta KJ 2002 The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52:154-179
166. Skowronski RJ, Peehl DM, Feldman D 1993 Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960
167. Feldman D, Skowronski RJ, Peehl DM 1995 Vitamin D and prostate cancer. Diet and cancer. New York: Plenum Press; 53-63
168. Kivineva M, Blauer M, Syvala H, Tammela T, Tuohimaa P 1998 Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol 66:121-127
169. Schwartz GG, Hulka BS 1990 Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Res 10:1307-1311
170. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P 2000 Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11:847-852
171. Yang ES, Maiorino CA, Roos BA, Knight SR, Burnstein KL 2002 Vitamin D-mediated growth inhibition of an androgen-ablated LN-CaP cell line model of human prostate cancer. Mol Cell Endocrinol 186:69-79
172. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, FeldmanD1994 Antiprolifeartive effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54:805-810
173. Krishnan AV, Peehl DM, Feldman D 2003 Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J Cell Biochem 88:363-371
174. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS 1997 Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50:999-1006
175. Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L 1999 Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 8:241-248
176. Polek TC, Murthy S, Blutt SE, Boehm MF, Zou A, Weigel NL, Allegretto EA 2001 Novel nonsecostroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. Prostate 49:224-233
177. Vegesna V, O'Kelly J, Said J, Uskokovic M, Binderup L, Koeffler HP 2003 Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo. Anticancer Res 23:283-289
178. Drivdahl RH, Loop SM, Andress DL, Ostenson RC 1995 IGF-binding proteins in human prostate tumor cells: expression and regulation by 1,25- dihydroxyvitamin D3. Prostate 26:72-79
179. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP 1997 Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1, and E-cadherin. J Mol Endocrinol 19:15-27
180. Huynh H, Pollak M, Zhang JC 1998 Regulation of insulin-like growth factor binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25-(OH)2D3 and its analog EB 1089. Int J Oncol 13:137-143
181. Boyle BJ, Zhao XY, Cohen P, Feldman D 2001 Insulin-like growth factor binding protein-3 mediates 1 α, 25-dihydroxyvitamin D3 growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165:1319-1324
182. Ly LH, Zhao XY, Holloway L, Feldman D 1999 Liarozole acts synergistically with 1α, 25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 140:2071-2076
183. Peehl DM, Seto E, Hsu JY, Feldman D 2002 Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analog EB 1089 on prostate cancer cell. J Urol 168:1583-1588
184. Zhao XY, Ly LH, Peehl DM, Feldman D 1997 1α,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 138:3290-3298
185. Zhao XY, Peehl DM, Navone NM, Feldman D 2000 1α, 25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgendependent and androgen-independent mechanisms. Endocrinology 141:2548-2556
186. Gross C, Stamey T, Hancock S, FeldmanD1998 Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 159:2035-2040
187. Koshizuka K, Koike M, Kubota T, Said J, Binderup L, Koeffler HP 1998 Novel vitamin D3 analog (CB1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo. Int J Oncol 13:421-428
188. Wang Q, Yang W, Uytingco MS, Christakos S, Weider R 2000 1,25-dihydroxyvitamin D3 and all-trans-retinoic acid sensitizes breast cancer cells to chemotherapy-induced cell death. Cancer Res 60:2040-2048
189. Hershberger PA, Yu W-D, Modzelewski RA, Rueger RM, Johnson CS, Trump DL 2001 Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7:1043-1051
190. Beer TM, Eilers KM, Garazotto M, Egorin MJ, Lowe BA, Henner WD 2003 Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21:123-128
191. Crescioli C, Villari D, Forti G, Ferruzzi P, Petrone L, Vannelli GB, Adorini L, Salerno R, Serio M, Maggi M 2002 Des (1-3) IGF-Istimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue. Mol Cell Endocrinol 198:69-75
192. De Bellis A, Crescioli C, Grappone C, Milani S, Ghiandi P, Forti G, Serio M 1998 Expression and cellular localization of keratinocyte growth factor and its receptor in human hyperplastic prostate tissue. J Clin Endocrinol Metab 83:2186-2191
193. Crescioli C, Maggie M, Vannelli GB, Luconi M, Salerno R, Barni T, Gulisano M, Forti G, Serio M 2000 Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. J Clin Endocrinol Metab 85:2576-2583
194. Crescioli C, Ferruzzi P, Caporali A, Mancina R, Comerci A, Muratori M, Scaltriti M, Vannelli GB, Smiroldo S, Mariani R, Villari D, Bettuzzi S, Serio M, Adorini L, Maggi M 2003 Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog. Endocrinology 144:3046-3057
195. Polar MK, Gennings C, Park M, Gupta MS, Gewirtz DA 2003 Effect of the vitamin D3 analog ILX 23-7553 on apoptosis and sensitivity to fractionated radiation in breast tumor cells and normal human fibroblasts. Cancer Chemother Pharmacol 51:415-421
196. Garland FC, Garland CF, Gorham ED, Young JF 1990 Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 19:614-622
197. John EM, Schwartz GG, Dreon DM, Koo J 1999 Vitamin D and breast cancer risk: the NHANES epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 8:399-406
198. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW, Pinkel D 2000 Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 25:144-146
199. Mawer EB, Walls J, Howell A, Davies M, Ratcliffe WA, Bundred NJ 1997 Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab 82:118-122
200. Bortman P, Folgueira MAAK, Katayama MLH, Snitcovsky IML, Brentani MM 2002 Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells: a mini review. Braz J Med Biol Res 35:1-9
201. Friedrich M, Axt-Fliedner R, Villena-Heinsen C, Tilgen W, Schmidt W, Reichrath J 2002 Analysis of vitaminDreceptor (VDR) and retinoid X receptor α in breast cancer. Histochem J 34:35-40
202. Flanagan L, Packman K, Juba B, O'Neill S, Tenniswood M, Welsh J 2003 Efficacy of vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J Steroid Biochem Mol Biol 84:181-192
203. Wu G, Fan RS, Li W, Ko TC, Brattain MG 1997 Modulation of cell cycle control by vitamin D3 and its analogue, EB 1089, in human breast cancer cells. Oncogene 15:1555-1563
204. Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J 2001 Inhibitory effects of 1α,25-dihydroxyvitamin D3 on the G1-S phasecontrolling machinery. Mol Endocrinol 15:1370-1380
205. Inoue T, Kamiyama J, Sakai T 1999 Sp1 and NF-Y synergistically mediate the effect of vitamin D3 in the p27Kip1 gene promoter that lacks vitamin D response elements. J Biol Chem 274:32309-32317
206. 3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol 142:57-65
207. Koli K, Keski-Oja J 1995 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor β 1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res 55:1540-1546
208. 3, retinoic acid and dexamethasone. Anticancer Drugs 4:201-208
209. Pan Q, Simpson RU 2001 Antisense knockout of HOXB4 blocks 1,25-dihydroxyvitamin D3 inhibition of c-myc expression. J Endocrinol 169:153-159
210. Rozen F, Yang XF, Huynh H, Pollak M 1997 Antiproliferative action of vitamin D-related compounds and insulin-like growth factor binding protein 5 accumulation. J Natl Cancer Inst 89:652-656
211. Colston KW, Perks CM, Xie SP, Holly JM 1998 Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 20:157-162
212. Hansen CM, Frandsen TL, Brunner N, Binderup L 1994 1α,25- Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 12:195-202
213. El Abdaimi K, Dion N, Papavasiliou V, Cardinal PE, Binderup L, Goltzman D, Ste-Marie LG, Kremer R 2000 The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res 60:4412-4418
214. 3 inhibits angiogenesis in vitro and in vivo. Circ Res 87:214-220
215. Sundaram S, Gewirtz DA 1999 The vitamin D3 analog EB 1089 enhances the response of human breast tumor cells to radiation. Radiat Res 152:479-486
216. Sundaram S, Chaudhry M, Reardon D, Gupta M, Gewirtz DA 2000 EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells to radiation. Breast Cancer Res Treat 63:1-10
217. Chaudhry M, Sundaram S, Gennings C, Carter H, Gewirtz DA 2001 The vitamin D analog ILX-23-7553 enhances the response to adriamycin and radiation in MCF-7 breast tumor cells. Cancer Chemother Pharmacol 47:429-436
218. 5, a synthetic analog of vitamin D. Mutat Res 523-524:253-264
219. Vandewalle B, Adenis A, Hornez L, Revillion F, Lefebvre J 1994 1,25-Dihydroxyvitamin D3 receptors in normal and malignant human colorectal tissues. Cancer Lett 86:67-73
220. Kallay E, Pietschmann P, Toyokuni S, Bajna E, Hahn P, Mazzucco K, Bieglmayer C, Kato S, Cross HS 2001 Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis 22:1429-1435
221. Bettoun DJ, Buck 2nd DW, Lu J, Khalifa B, Chin WW, Nagpal S 2002 A vitamin D receptor-Ser/Thr phosphatase-p70 S6 kinase complex and modulation of its enzymatic activities by the ligand. J Biol Chem 277:24847-24850
222. 3 analog (Ro 25-6760) inhibits human colon cancer in vitro via apoptosis. Int J Oncol 14:979-985
223. Palmer HG, Gonzalez-Sancho J, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, Munoz A 2001 Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signaling. J Cell Biol 154:369-387
224. Zhao X, Feldman D 1993 Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. Endocrinology 132:1808-1814
225. Gaschott T, Steinhilber D, Milovic V, Stein J 2001 Tributyrin, a stable and rapidly absorbed prodrug of butyric acid, enhances antiproliferative effects of dihydroxycholecalciferol in human colon cancer cells. J Nutr 131:1839-1843
226. Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A 2000 Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 60:2304-2312
227. Gaschott T, Steinmeyer A, Steinhilber D, Stein J 2002 ZK 156718, a low calcemic, antiproliferative, and prodifferentiating vitamin D analog. Biochem Biophys Res Commun 290:504-509
228. Hofer H, Ho G, Peterlik M, Uskokovic MR, Lee JK, White MC, Posner GH, Cross HS 1999 Biological effects of 1-hydroxy- and 1β-(hydroxymethyl)- vitamin D compounds relevant for potential colorectal cancer therapy. J Pharmacol Exp Ther 291:450-455
229. Palmer HG, Sanchez-Carbayo M, Ordonez-Moran P, Larriba MJ, Cordon-Cardo C, Munoz A 2003 Genetic signatures of differentiation induced by 1α,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res 63:7799-7806
230. 3. Cancer Res 47:21-25
231. Belleli A, Shany S, Levy J, Guberman R, Lamprecht SA 1992 A protective role of 1,25-dihydroxyvitamin D3 in chemically induced rat colon carcinogenesis. Carcinogenesis 13:2293-2298
232. Wali RK, Bissonnette M, Khare S, Hart J, Sitrin MD, Brasitus TA 1995 1 α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analogue of 1 α,25-dihydroxyvitamin D3, inhibits azoxymethane-induced colonic tumorigenesis. Cancer Res 55:3050-3054
233. min mouse. Cancer Res 62:741-746
234. Wali RK, Khare S, Tretiakova M, Cohen G, Nguyen L, Hart J, Wang J, Wen M, Ramaswamy A, Joseph L, Sitrin M, Brasitus T, Bissonnette M 2002 Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin. Cancer Epidemiol Biomarkers Prev 11:1653-1662
235. Honma Z, Nandan D, Sly L, Knutson KL, Herrera-Velit P, Reiner NE 1999 1α,25-Dihydroxyvitamin D3-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex. J Exp Med 190:1583-1594
236. Niitsu N, Umeda M, Honma Y 2000 Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs. Leuk Res 24:1-9
237. James SY, Williams MA, Newland AC, Colston KW 1999 Leukemia cell differentiation: cellular and molecular interactions of retinoids and vitamin D. Gen Pharmacol 32:143-154
238. Kanatani Y, Makishima M, Ishikawa I, Ogasawara Y, Kawahara N, Motoyoshi K, Nagata N, Honma Y 1998 A novel uracil analog, 6-chloro-5-(2-propenyl)uracil, preferentially enhances growth inhibition and differentiation of myeloid leukemia cells induced by 1α,25-dihydroxyvitamin D3. Exp Hematol 26:198-206
239. Funato K, Miyazawa K, Yaguchi M, Gotoh A, Ohyashiki K 2002 Combination of 22-oxa-1,25-dihydroxyvitamin D3, a vitamin D3 derivative, with vitamin K2 (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cells. Leukemia 16:1519-1527
240. Rots NY, Liu M, Anderson EC, Freedman LP 1998 A differential screen for ligand-regulated genes: identification of HoxA10 as a target of vitamin D3 induction in myeloid leukemic cells. Mol Cell Biol 18:1911-1918
241. Motomura S, Kanamori H, Maruta A, Kodama F, Ohkubo T 1991 The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol 38:67-68
242. Mellibovsky L, Diez A, Perez-Vila E, Serrano S, Nacher M, Aubia J, Supervia A, Recker RR 1998 Vitamin D treatment in myelodysplastic syndromes. Br J Haematol 100:516-520
243. Santini V, Ferrini PR 1998 Differentiation therapy of myelodysplastic syndromes: fact of fiction? Br J Heamatol 102:1124-1138
244. Enepekides DJ, Black MJ, White JH 1999 The independent and combined effects of RAR-, RXR-, and VDR-selective ligands on the growth of squamous cell carcinoma in vitro. J Otolaryngol 28:83-89
245. Crowe DL, Shuler CF 1998 Increased cdc2 and cdk2 kinase activity by retinoid X receptor γ-mediated transcriptional down-regulation of the cyclin-dependent kinase inhibitor p21Cip1/WAF1 correlates with terminal differentiation of squamous cell carcinoma lines. Cell Growth Differ 9:619-627
246. Di Cunto F, Topley G, Calautti E, Hsiao J, Ong L, Seth PK, Dotto GP 1998 Inhibitory function of p21Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science 280:1069-1072
247. 3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol 16:1243-1256
248. Jenner RG, Maillard K, Cattini N, Weiss RA, Boshoff C, Wooster R, Kellam P 2003 Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci USA 100:10399-10404
249. Masood R, Nagpal S, Zheng T, Cai J, Tulpule A, Smith DL, Gill PS 2000 Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood 96:3188-3194
250. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357
251. Lutzow-Holm C, De Angelis P, Clausen OP 1996 Calcitriol and its analog KH 1060 induce similar changes in keratinocyte cell cycle progression after topical application to mouse skin. A bromodeoxyuridine pulse-chase flow cytometric study. J Investig Dermatol Symp Proc 1:54-59
252. Bland R 2000 Steroid hormone receptor expression and action in bone. Clin Sci (Lond) 98:217-240
253. Gallagher JC, Riggs BL 1990 Action of 1,25-dihydroxyvitamin D3 on calcium balance and bone turnover and its effect on vertebral fracture rate. Metabolism 39(4 Suppl 1):30-34
254. Gallagher JC, Goldgar D 1990 Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 113:649-655
255. Tilyard MW, Spears GF, Thomson J, Dovey S 1992 Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357-362
256. Lau KH, Baylink DJ 1999 Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 65:295-306
257. Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K, Ogata E 1999 The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int 65:311-316
258. Uchiyama Y, HiguchI Y, Takeda S, Masaki T, Shira-Ishi A, Sato K, Kubodera N, Ikeda K, Ogata E 2002 ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 30:582-588
259. Tanaka Y, Nakamura T, Nishida S, Suzuki K, Takeda S, Sato K, Nishii Y 1996 Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats. J Bone Miner Res 11:325-336
260. Ono Y, Kawase A, Watanabe H, Shiraishi A, Takeda S, Higuchi Y, Sato K, Yamauchi T, Mikami T, Kato M, Tsugawa N, Okano T, Kubodera N 1998 Syntheses and preventive effects of analogues related to 1α,25-dihydroxy-2β-(3- hydroxypropoxy)vitamin D3 (ED-71) on bone mineral loss in ovariectomized rats. Bioorg Med Chem 6:2517-2523
261. Kubodera N, Tsuji N, Uchiyama Y, Endo K 2003 A new active vitamin D analog, ED-71, causes increase in bone mass with preferential effects on bone in osteoporotic patients. J Cell Biochem 88:286-289
262. Peleg S, Uskokovic M, Ahene A, Vickery B, Avnur Z 2002 Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats. Endocrinology 143:1625-1636
263. Peleg S, Ismail A, Uskokovic MR, Avnur Z 2003 Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem 88:267-273
264. Shevde NK, Plum LA, Clagett-Dame M, Yamamoto H, Pike JW, DeLuca HF 2002 A potent analog of 1,25-dihydroxyvitamin D3 selectively induces bone formation. Proc Natl Acad Sci USA 99:13487-13491
265. Yamamoto H, Shevde NK, Warrier A, Plum LA, DeLuca HF, Pike JW 2003 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J Biol Chem 278:31756-31765
266. Li YC, Kong J, Wei M, Chen Z-F, Liu SQ, Cao L-P 2002 1,25- Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229-238
267. Wallace AC, Laskowski RA, Thornton JM 1995 LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8:127-134
268. McDonald IK, Thornton JM 1994 Satisfying hydrogen bonding potential in proteins. J Mol Biol 238:777-793
269. Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ, Rosmorduc O, Erlinger S, Bach Hansen J, Steward WP, Skov T, Burcharth F, Evans TR 2003 A phase II study of the vitamin D analogue seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 89:252-257
270. Perez A, Raab R, Chen TC, Turner A, Holick MF 1996 Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 134:1070-1078
271. van de Kerkhof PC, Berth-Jones J, Griffiths CE, Harrison PV, Honigsmann H, Marks R, Roelandts R, Schopf E, Trompke C 2002 Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol 146:414-422
272. Barker JN, Ashton RE, Marks R, Harris RI, Berth-Jones J 1999 Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 141:274-278
273. Vickery BH, Avnur Z, Uskokovic M, Peleg S, New tissue-selective vitamin D receptor modulators (VDRMs). Proc 11th International Vitamin D Workshop, Nashville, TN, 2000, p 221
274. Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E 1998 Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25- dihydroxyvitamin D2. Am J Kidney Dis 32:S48-S54
275. Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Ohashi Y, Ogata E, Slatopolsky E, Kurokawa K 2002 Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study. Nephrol Dial Transplant 17(Suppl 10):28-36
276. Onate SA, Tsai SY, Tsai MJ, O'Malley BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-1370
277. Hong H, Kohli K, Garabedian MJ, Stallcup MR 1997 GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol 17:2735-2744
278. Li H, Gomes PJ, Chen JD 1997 RAC3, a steroid/nuclear receptorassociated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci USA 94:8479-8484
279. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG 1997 The transcriptional coactivator p/CIP binds CBP and mediates nuclear receptor function. Nature 387:677-684
280. Masuyama H, Brownfield CM, St-Arnaud R, MacDonaldPN1997 Evidence for ligand-dependent intramolecular folding of the AF-2 domain in vitamin D receptor-activated transcription and coactivator interaction. Mol Endocrinol 11:1507-1517
281. vom Baur E, Zechel C, Heery D, Heine MJ, Garnier JM, Vivat V, Le Douarin B, Gronemeyer H, Chambon P, Losson R 1996 Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J 15:110-124
282. Tagami T, Lutz WH, Kumar R, Jameson JL 1998 The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators. Biochem Biophys Res Commun 253:358-363
283. 3. Chem Biol 6:265-275
284. Mortensen JT, Lichtenberg J, Binderup L 1996 Toxicity of 1,25-dihydroxyvitamin D3, tacalcitol, and calcipotriol after topical treatment in rats. J Investig Dermatol Symp Proc 1:60-63